Moyamoya Disease Incidence Rates in India
Moyamoya Disease Incidence Rates in India Moyamoya disease is a rare, progressive cerebrovascular disorder characterized by the narrowing or occlusion of the internal carotid arteries and their main branches at the base of the brain. This constriction leads to the development of a network of fragile collateral vessels that resemble a “puff of smoke” on angiographic imaging, which is where the disease gets its name—”moyamoya” meaning “hazy” or “puff of smoke” in Japanese. Although initially described in Japan, moyamoya disease is now recognized worldwide, including in India, where its true incidence and prevalence are gradually being understood.
In India, the incidence rates of moyamoya disease are believed to be lower compared to East Asian countries such as Japan, Korea, and China, where the disease is more prevalent. However, recent studies and clinical observations suggest that moyamoya may be underdiagnosed or misdiagnosed in the Indian population due to limited awareness and access to specialized neuroimaging facilities. The actual prevalence remains uncertain, but available data indicates that while it is a rare condition, it is not negligible.
The demographic profile of moyamoya in India seems to align with global patterns, affecting both children and adults, though children often present with ischemic strokes or transient ischemic attacks, whereas adults may experience hemorrhagic strokes or neurological deficits. The disease appears to have a slight female preponderance and can occur across various ethnic groups within India. Genetic factors are suspected to play a role, as mutations in the RNF213 gene have been associated with moyamoya in other populations, and similar genetic links are being explored in Indian cohorts.
Diagnosis of moyamoya disease in India relies heavily on advanced neuroimaging techniques such as magnetic resonance angiography (MRA), computed tomography angiography (CTA), and digital subtraction angiography (DSA). Early diagnosis is crucial, as timely surgical interve
ntion—such as revascularization procedures—can significantly reduce the risk of strokes and improve functional outcomes. Unfortunately, limited healthcare access and lack of awareness often delay diagnosis, especially in rural and underserved regions.
The incidence of moyamoya in India is likely to increase as awareness improves and diagnostic facilities become more widely available. Epidemiological studies are ongoing to better understand regional variations and the true burden of the disease. Efforts to develop a national registry and promote research into genetic and environmental factors are essential to formulate effective management strategies and improve patient outcomes.
In conclusion, while moyamoya disease remains a rare condition in India, its clinical significance warrants increased attention from healthcare providers and policymakers. By enhancing diagnostic capabilities and awareness, India can better identify affected individuals early, offering them surgical and medical options that can dramatically alter their prognosis. Continued research will shed more light on the disease’s incidence and help tailor preventive and therapeutic approaches suited to the Indian population.